

The 2023 Monitoring Program* (Draft)

The following substances are placed on the 2023 Monitoring Program:

1. Anabolic Agents:

In and ***Out-of-Competition***: Ecdysterone

2. Peptides Hormones, Growth Factors, Related Substances, and Mimetics:

In and ***Out-of-Competition***: Gonadotrophin-releasing hormone (GnRH) analogs in females under 18 years only.

3. Beta-2 Agonists:

In and ***Out-of-Competition***: Salmeterol and vilanterol below the *Minimum Reporting Level*.

4. Hypoxen (polyhydroxyphenylene thiosulfonate sodium):

In and ***Out-of-Competition***

5. Stimulants:

In-Competition only: Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol and synephrine.

6. Narcotics:

In-Competition only: Codeine, dermorphin (and its analogs), hydrocodone and tramadol.

*The World Anti-Doping Code (Article 4.5) states: "WADA, in consultation with Signatories and governments, shall establish a monitoring program regarding substances which are not on the Prohibited List, but which WADA wishes to monitor in order to detect potential patterns of misuse in sport."